About this Journal Submit a Manuscript Table of Contents
Experimental Diabetes Research
Volume 2012 (2012), Article ID 758614, 11 pages
http://dx.doi.org/10.1155/2012/758614
Research Article

Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Diet-Induced Metabolic Syndrome in Rats

1School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
2Department of Biological and Physical Sciences, University of Southern Queensland, Toowoomba, QLD 4350, Australia
3Department of Entomology and University of California Davis Cancer Center, University of California, Davis, CA 95616, USA

Received 30 May 2011; Revised 15 July 2011; Accepted 15 July 2011

Academic Editor: Yingmei Zhang

Copyright © 2012 Abishek Iyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Iyer, D. P. Fairlie, J. B. Prins, B. D. Hammock, and L. Brown, “Inflammatory lipid mediators in adipocyte function and obesity,” Nature Reviews Endocrinology, vol. 6, no. 2, pp. 71–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Iyer and L. Brown, “Lipid mediators and inflammation in glucose intolerance and insulin resistance,” Drug Discovery Today: Disease Mechanisms, vol. 7, no. 3-4, pp. e191–e197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. V. Potenza and J. I. Mechanick, “The metabolic syndrome: definition, global impact, and pathophysiology,” Nutrition in Clinical Practice, vol. 24, no. 5, pp. 560–577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. K. Simmons, K. G. Alberti, E. A. Gale et al., “The metabolic syndrome: useful concept or clinical tool? Report of a WHO expert consultation,” Diabetologia, vol. 53, no. 4, pp. 600–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. F. van Gaal, I. L. Mertens, and C. E. De Block, “Mechanisms linking obesity with cardiovascular disease,” Nature, vol. 444, no. 7121, pp. 875–880, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988. View at Scopus
  7. P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg, “Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation,” Circulation, vol. 111, no. 11, pp. 1448–1454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Z. Zimmet, K. G. Alberti, and J. E. Shaw, “Mainstreaming the metabolic syndrome: a definitive defenition,” Medical Journal of Australia, vol. 183, no. 4, pp. 175–176, 2005. View at Scopus
  9. E. Ferrannini, “Is insulin resistance the cause of the metabolic syndrome?” Annals of Medicine, vol. 38, no. 1, pp. 42–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. E. Symonds, S. P. Sebert, M. A. Hyatt, and H. Budge, “Nutritional programming of the metabolic syndrome,” Nature Reviews Endocrinology, vol. 5, no. 11, pp. 604–610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. H. Habenicht, P. Salbach, M. Goerig et al., “The LDL receptor pathway delivers arachidonic acid for eicosanoid formation in cells stimulated by platelet-derived growth factor,” Nature, vol. 345, no. 6276, pp. 634–636, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Kudo and M. Murakami, “Phospholipase A2 enzymes,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 3–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Lambeau and M. H. Gelb, “Biochemistry and physiology of mammalian secreted phospholipases A 2,” Annual Review of Biochemistry, vol. 77, pp. 495–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Shi, M. Ding, Z. Dong et al., “Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-κB activation, and TNF-α production,” Molecular and Cellular Biochemistry, vol. 199, no. 1-2, pp. 93–102, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ,” Science, vol. 293, no. 5535, pp. 1673–1677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. J. P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006. View at Scopus
  17. J. D. Imig and B. D. Hammock, “Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases,” Nature Reviews Drug Discovery, vol. 8, no. 10, pp. 794–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Inceoglu, K. Wagner, N. H. Schebb et al., “Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5093–5097, 2011. View at Publisher · View at Google Scholar
  19. J. D. Imig, X. Zhao, C. Z. Zaharis et al., “An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension,” Hypertension., vol. 46, no. 4, pp. 975–981, 2005. View at Scopus
  20. N. Chiamvimonvat, C. M. Ho, H. J. Tsai, and B. D. Hammock, “The soluble epoxide hydrolase as a pharmaceutical target for hypertension,” Journal of Cardiovascular Pharmacology, vol. 50, no. 3, pp. 225–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Loch, A. Hoey, C. Morisseau, B. O. Hammock, and L. Brown, “Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase,” Cell Biochemistry and Biophysics, vol. 47, no. 1, pp. 87–97, 2007. View at Scopus
  22. J. Y. Liu, H. J. Tsai, S. H. Hwang, P. D. Jones, C. Morisseau, and B. D. Hammock, “Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation,” British Journal of Pharmacology, vol. 156, no. 2, pp. 284–296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. K. Panchal, H. Poudyal, A. Iyer et al., “High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats,” Journal of Cardiovascular Pharmacology, vol. 57, no. 1, pp. 611–624, 2011. View at Publisher · View at Google Scholar
  24. A. Iyer and L. Brown, “Fermented wheat germ extract (Avemar) in the treatment of cardiac remodeling and metabolic symptoms in rats,” Evidence-Based Complementary and Alternative Medicine, Article ID 508957, pp. 1–10, 2011. View at Publisher · View at Google Scholar
  25. A. Iyer, A. Fenning, J. Lim et al., “Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats: research paper,” British Journal of Pharmacology, vol. 159, no. 7, pp. 1408–1417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Chan, A. Fenning, A. Iyer, A. Hoey, and L. Brown, “Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats,” Current Pharmaceutical Biotechnology, vol. 12, no. 3, pp. 429–436, 2011. View at Publisher · View at Google Scholar
  27. S. E. Litwin, S. E. Katz, J. P. Morgan, and P. S. Douglas, “Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat,” Circulation, vol. 89, no. 1, pp. 345–354, 1994. View at Scopus
  28. J. D. Imig, X. Zhao, J. H. Capdevila, C. Morisseau, and B. D. Hammock, “Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension,” Hypertension, vol. 39, no. 2, pp. 690–694, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. B. M. de Taeye, C. Morisseau, J. Coyle et al., “Expression and regulation of soluble epoxide hydrolase in adipose tissue,” Obesity, vol. 18, no. 3, pp. 489–498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. Seubert, C. J. Sinal, J. Graves et al., “Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function,” Circulation Research, vol. 99, no. 4, pp. 442–450, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. D. C. Zeldin, J. Foley, J. E. Boyle et al., “Predominant expression of an arachidonate epoxygenase in islets of langerhans cells in human and rat pancreas,” Endocrinology, vol. 138, no. 3, pp. 1338–1346, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. J. R. Falck, S. Manna, J. Moltz, N. Chacos, and J. Capdevila, “Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets,” Biochemical and Biophysical Research Communications, vol. 114, no. 2, pp. 743–749, 1983.
  33. P. Luo, H. H. Chang, Y. Zhou et al., “Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 2, pp. 430–438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Luria, A. Bettaieb, Y. Xi et al., “Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 22, pp. 9038–9043, 2011. View at Publisher · View at Google Scholar
  35. C. R. Lee, K. E. North, M. S. Bray et al., “Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study,” Human Molecular Genetics, vol. 15, no. 10, pp. 1640–1649, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. K. P. Burdon, A. B. Lehtinen, C. D. Langefeld et al., “Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study,” Diabetes and Vascular Disease Research, vol. 5, no. 2, pp. 128–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Yang, K. Schmelzer, K. Georgi, and B. D. Hammock, “Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry,” Analytical Chemistry, vol. 81, no. 19, pp. 8085–8093, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Morisseau, B. Inceoglu, K. Schmelzer et al., “Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids,” Journal of Lipid Research, vol. 51, no. 12, pp. 3481–3490, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. F. Moghaddam, D. F. Grant, J. Cheek, J. F. Greene, K. C. Williamson, and B. D. Hammock, “Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase,” Nature Medicine, vol. 3, no. 5, pp. 562–566, 1997. View at Scopus
  40. D. Xu, N. Li, Y. He et al., “Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 49, pp. 18733–18738, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. K. R. Schmelzer, L. Kubala, J. W. Newman, I.-H. Kim, J. P. Eiserich, and B. D. Hammock, “Soluble epoxide hydrolase is a therapeutic target for acute inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 28, pp. 9772–9777, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Y. Liu, J. Yang, B. Inceoglu et al., “Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model,” Biochemical Pharmacology, vol. 79, no. 6, pp. 880–887, 2010. View at Publisher · View at Google Scholar · View at Scopus